ArticleCureus2024

Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Postpartum High-Risk Basal-Type Breast Cancer.

Heng Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.